Veterinary Oncology - Global Strategic Business Report

Global Veterinary Oncology Market to Reach $727.8 Million by 2030

The global market for Veterinary Oncology estimated at US$233.6 Million in the year 2022, is projected to reach a revised size of US$727.8 Million by 2030, growing at a CAGR of 15.3% over the analysis period 2022-2030. Chemotherapy, one of the segments analyzed in the report, is projected to record 16.8% CAGR and reach US$246 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Radiology segment is readjusted to a revised 13.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $63.6 Million, While China is Forecast to Grow at 19.9% CAGR

The Veterinary Oncology market in the U.S. is estimated at US$63.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$168 Million by the year 2030 trailing a CAGR of 19.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.5% and 13.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12% CAGR.

Select Competitors (Total 42 Featured) -

• Accuray Incorporated
• Boehringer Ingelheim International GmbH
• Elanco
• Karyopharm Therapeutics, Inc.
• Morphogenesis, Inc.
• Nippon Zenyaku Kogyo Co., Ltd.
• One Health
• PetCure Oncology
• Regeneus Ltd.
• Varian Medical System, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year